Residency · Residency · Physical Medicine Rehabilitation
Complex Regional Pain Syndrome: Diagnosis and Multidisciplinary Management
Overview
Chronic pain condition characterized by pain disproportionate to inciting event, with sensory, vasomotor, sudomotor/edema, and motor/trophic changes. Previously termed reflex sympathetic dystrophy (CRPS type I) and causalgia (CRPS type II). CRPS type I: no identifiable nerve injury; CRPS type II: associated with documented nerve injury. Incidence: 5-26 per 100,000 person-years.
Female:male ratio approximately 3-4:1. Most common age: 40-60 years. Upper extremity affected more than lower extremity (60% vs 40%). Common precipitants: fractures (most common), surgery, soft tissue injury, immobilization.
Budapest Diagnostic Criteria (2003, validated 2010)
Must meet ALL four requirements:
1. Continuing pain disproportionate to inciting event
2. At least ONE sign in TWO or more of these categories:
Sensory: hyperalgesia and/or allodynia. Vasomotor: temperature asymmetry, skin color changes/asymmetry. Sudomotor/edema: edema, sweating changes/asymmetry. Motor/trophic: decreased ROM, motor dysfunction (weakness, tremor, dystonia), trophic changes (hair, nail, skin).
3. At least ONE symptom (patient-reported) in THREE or more categories:
Sensory: hyperesthesia, hyperalgesia. Vasomotor: temperature asymmetry, skin color changes. Sudomotor/edema: edema, sweating changes. Motor/trophic: decreased ROM, motor dysfunction, trophic changes.
4. No other diagnosis better explains signs and symptoms
<image>Budapest diagnostic criteria for CRPS with clinical photographs showing vasomotor, sudomotor, and trophic changes</image>
Pathophysiology
Multimechanistic - no single unifying theory.
Peripheral Mechanisms
Neurogenic inflammation: release of substance P, CGRP from sensitized nociceptors. Peripheral sensitization with upregulated sodium channels. Small fiber neuropathy (even in CRPS type I). Oxidative stress and local tissue hypoxia.
Central Mechanisms
Central sensitization: dorsal horn wind-up, NMDA receptor activation. Cortical reorganization: shrinkage of affected hand representation in somatosensory cortex. Disinhibition of pain-processing pathways. Body perception disturbance (affected limb feels foreign, larger).
Autonomic Dysfunction
Early (warm phase): inhibition of sympathetic vasoconstriction → warmth, redness, edema. Late (cold phase): sympathetic hyperactivity → cold, pale/cyanotic, dry skin. Sympatho-afferent coupling: norepinephrine activates nociceptors.
Inflammatory/Immune
Elevated pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). Autoantibodies against autonomic receptors identified in some patients. Mast cell activation and neurogenic inflammation.
Psychological Factors
NOT a psychogenic condition. Psychological distress is a consequence, not a cause. Anxiety, depression, catastrophizing may modulate pain processing. Prior life stress may be a vulnerability factor.
Clinical Stages (Classic Description)
Note: not all patients follow this staging; it has limited clinical utility.
Stage 1 (Acute/Warm) - 0-3 months
Burning pain, hyperalgesia, allodynia. Warm, red, edematous limb. Increased sweating. Increased hair and nail growth.
Stage 2 (Dystrophic) - 3-6 months
Persistent pain, spreading. Cool, cyanotic skin. Decreased hair growth, brittle nails. Early joint stiffness. Osteopenia on X-ray.
Stage 3 (Atrophic) - >6 months
Pain may decrease or persist. Pale, cool, atrophic skin. Joint contractures. Significant osteoporosis. Muscle wasting. Often irreversible changes.
| Stage | Timeframe | Temperature | Skin Appearance | Edema | Trophic Changes | Prognosis |
|---|---|---|---|---|---|---|
| 1 (Acute/Warm) | 0-3 months | Warm | Red, flushed | Present | Increased hair/nail growth | Best if treated early |
| 2 (Dystrophic) | 3-6 months | Cool | Cyanotic | Variable | Decreased hair, brittle nails | Moderate |
| 3 (Atrophic) | >6 months | Cool | Pale, atrophic | Minimal | Contractures, osteoporosis, wasting | Often irreversible |
Diagnostic Workup
CRPS is a clinical diagnosis - no single confirmatory test. Supportive investigations: Triple-phase bone scan: increased uptake in affected region (sensitivity 50-70%, specificity 80-90%), most useful in early CRPS. Plain radiographs: patchy osteoporosis (Sudeck atrophy), occurs later.
Temperature asymmetry: > 1°C difference between affected and unaffected side (quantitative thermography). Quantitative sudomotor axon reflex test (QSART): asymmetric sweating. MRI: bone marrow edema, soft tissue edema (nonspecific). Electrodiagnostic studies: normal in CRPS type I; nerve injury findings in CRPS type II. Exclude: infection, DVT, fracture, compartment syndrome, vascular insufficiency.
<image>Diagnostic workup for CRPS showing triple-phase bone scan, thermography, and radiographic findings</image>
Treatment Approach
Principles
Early, aggressive, multidisciplinary treatment. Functional restoration is the primary goal. Graded exposure to movement and sensation. Address fear-avoidance and pain catastrophizing. Treatment becomes less effective with chronicity.
Rehabilitation/Physical Therapy (Foundation of Treatment)
Graded Motor Imagery (GMI)
Three-stage progressive program: 1. Laterality recognition: identifying left vs. right limb images (activates premotor cortex without pain). 2. Motor imagery: imagining movements of the affected limb (further cortical activation). 3. Mirror therapy: watching unaffected limb in mirror while performing bilateral movements (visual-motor cortical normalization).
Evidence: Level 1 for pain reduction and function improvement. Requires daily practice (10-15 minutes, multiple times daily).
Desensitization
Progressive exposure to increasingly intense stimuli. Graded textures, temperatures, pressures applied to affected area. Addresses allodynia and hyperesthesia. Must be done gradually to avoid flare.
Active Exercise
Pain-free or pain-limited active ROM. Progressive loading and strengthening. Aquatic therapy may be better tolerated. Avoid immobilization (worsens CRPS). Stress loading program: scrubbing and carrying activities.
Edema Management
Elevation, compression garments, retrograde massage. Manual lymphatic drainage. Contrast baths (controversial - may worsen vasomotor instability).
Pharmacologic Management
First-Line
NSAIDs: early anti-inflammatory effect. Corticosteroids: short course (prednisone 30-40 mg/day taper over 2-4 weeks) - most effective in early, inflammatory CRPS. Gabapentinoids: pregabalin 150-600 mg/day or gabapentin 900-3600 mg/day. Tricyclic antidepressants: nortriptyline or amitriptyline 25-150 mg.
Second-Line
Bisphosphonates: alendronate, neridronate, pamidronate IV. Address bone resorption component. Some evidence for pain reduction beyond bone effects. Neridronate has strongest evidence.
SNRIs: duloxetine 60-120 mg. Topical agents: lidocaine 5% patches, capsaicin 8% patch, DMSO 50% cream (not available in US). Calcitonin: nasal spray, limited evidence.
Third-Line
Ketamine: IV infusions (low-dose subanesthetic). NMDA receptor antagonist addressing central sensitization. Growing evidence but variable protocols. Requires monitored setting.
Opioids: generally avoided; limited efficacy, risk of dependence. Low-dose naltrexone: emerging evidence, anti-neuroinflammatory mechanism. Immunoglobulin (IVIG): for autoimmune/inflammatory subtype, limited evidence.
Interventional Procedures
Sympathetic Nerve Blocks
Stellate ganglion block (upper extremity) or lumbar sympathetic block (lower extremity). Diagnostic: confirms sympathetically maintained pain (SMP) component. Therapeutic: temporary relief; series of blocks with concurrent therapy. Not all CRPS has SMP component (sympathetically independent pain also exists).
Spinal Cord Stimulation
Dorsal column stimulation for refractory CRPS. KEMSTIM and ACCURATE trials: Level 1 evidence for CRPS pain reduction. Consider after failure of conservative management (3-6 months). Trial stimulation before permanent implant. May improve function and quality of life.
Intrathecal Drug Delivery
Baclofen for CRPS-related dystonia. Opioid/ziconotide for refractory pain. Reserved for severe, refractory cases.
<image>Treatment algorithm for CRPS showing stepwise approach from rehabilitation through interventional procedures</image>
Prognosis
Early treatment (within 3-6 months) associated with better outcomes. 50-70% achieve significant improvement with multimodal treatment. 15-25% develop chronic, refractory CRPS. Spontaneous remission can occur. Recurrence rate: 10-30%. Spread to other limbs can occur (contralateral, ipsilateral).
Clinical Pearls
CRPS is a clinical diagnosis using Budapest criteria - no lab test or imaging study can confirm or exclude it. Early aggressive rehabilitation with graded motor imagery and desensitization is the foundation of treatment, not pharmacology. Short-course corticosteroids (prednisone taper) are most effective when CRPS is caught early in the inflammatory phase. Immobilization and protective guarding worsen CRPS - educate patients that movement is therapeutic despite being painful. If a patient with CRPS has dystonia, consider intrathecal baclofen trial - this is often a neglected treatment option.
References
- Harden RN, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for complex regional pain syndrome. Pain. 2010;150(2):268-274.
- Birklein F, et al. Complex regional pain syndrome: an update. Pain Rep. 2021;6(1):e929.
- Shim H, et al. Complex regional pain syndrome: a narrative review for the practising clinician. Br J Anaesth. 2019;123(2):e424-e433.
- Smart KM, et al. Mechanisms-based classifications of musculoskeletal pain. Clin J Pain. 2011;27(7):655-663.
- O'Connell NE, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev. 2013;(4):CD009416.
